VA-INTELSAT
26.6.2024 17:01:35 CEST | Business Wire | Press release
Intelsat, operator of the world’s largest integrated satellite and terrestrial network, signed a contract for a Starfish Otter servicing vehicle to provide life extension services to an Intelsat geostationary satellite, beginning in 2026. This landmark agreement reinforces Intelsat’s commitment to utilizing satellite servicing technologies to maximize the value its satellites can provide to customers and will mark Starfish’s first mission to provide services to a commercial satellite operator with Otter.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240626723807/en/
Starting in 2026, Starfish Space’s Otter will dock with a retired Intelsat satellite during a checkout campaign before maneuvering to dock with and service one of Intelsat’s operational satellites. (Courtesy: Starfish Space).
“For six decades, Intelsat has shown commitment to innovation and leveraging new technologies from throughout the industry,” said Jean-Luc Froeliger, Intelsat's Senior Vice President of Space Systems. “By engaging with emerging ventures, we create unique value for Intelsat while fostering a dynamic and competitive environment that drives advancement in space systems. Starfish is the perfect example of this kind of progress, and we look forward to utilizing the services provided by their Otter satellite to maximize the value the world’s largest geostationary satellite fleet can deliver for our customers.”
Intelsat has been a pioneer of extending satellite missions, signing its first agreement for satellite life extension in 2016, and procuring multiple additional life extension missions in recent years. The contract between Intelsat and Starfish represents a significant step for both companies, expanding the market for satellite servicing, and pushing the industry towards a new paradigm for satellite operations. With its Otter spacecraft, Starfish Space utilizes a small satellite architecture and breakthrough hardware and software technologies to provide rapid, flexible, and cost-effective on-orbit servicing missions for satellites.
Starfish will begin its first servicing mission for Intelsat in 2026. Initially, Otter will dock with and maneuver a retired Intelsat satellite in geostationary graveyard orbit. Following this initial operation, Otter will proceed to dock with and provide life extension service to an operational Intelsat satellite, using its onboard propulsion system to keep the client satellite in operational orbit for additional years of life.
“Starfish Space is delighted to be supporting Intelsat with services provided by Otter,” said Dr. Trevor Bennett, Co-Founder of Starfish Space. “They are an incredible team at the forefront of the industry and the Otter will help them deliver even more to their customers. We're also excited that this will be the first of many Otters that will make on-orbit servicing a standard part of satellite operations.”
About Intelsat
Intelsat’s global team of professionals is focused on providing seamless and secure, satellite-based communications to government, NGO and commercial customers through the company’s next-generation worldwide network and managed services. Bridging the digital divide by operating one of the world’s largest and most advanced satellite fleet and connectivity infrastructures, Intelsat enables people and their tools to speak over oceans, see across continents and listen through the skies to communicate, cooperate and coexist. Since its founding six decades ago, the company has been synonymous with satellite-industry “firsts” in service to its customers and the planet. Leaning on a legacy of innovation and focusing on addressing a new generation of challenges Intelsat team members now have their sights on the “next firsts” in space as they disrupt the field and lead in the digital transformation of the industry.
About Starfish Space
Starfish Space is developing the Otter servicing vehicle to extend the lives of satellites in geostationary orbit and dispose of space debris in low-Earth orbit. Starfish has secured contracts for its first Otter missions with Intelsat and the U.S. Space Force, two of the largest global satellite operators. The company launched its Otter Pup demonstration mission in June 2023 and is now delivering on several satellite RPOD missions including its Otter mission for Intelsat. For more information, please visit starfishspace.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240626723807/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release
The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom